Fotemustine is a nitrosourea alkylating agent used in the treatment of metastatic melanoma.

It is available in Europe but has not been approved by the United States FDA.

[1] A study[2] has shown that fotemustine produces improved response rates and but does not increase survival (over dacarbazine in the treatment of disseminated cutaneous melanoma.

The main toxicity was grade 3 to 4 neutropenia (51% with fotemustine v 5% with DTIC) and thrombocytopenia (43% v 6%, respectively).

This antineoplastic or immunomodulatory drug article is a stub.